Kakaraskoska Boceska, B;
Vilken, T;
Xavier, BB;
Kostyanev, T;
Lin, Q;
Lammens, C;
Ellis, S;
O'Brien, S;
da Costa, RMA;
Cook, A;
et al.
Kakaraskoska Boceska, B; Vilken, T; Xavier, BB; Kostyanev, T; Lin, Q; Lammens, C; Ellis, S; O'Brien, S; da Costa, RMA; Cook, A; Russell, N; Bielicki, J; Riddell, A; Stohr, W; Walker, AS; Berezin, EN; Roilides, E; De Luca, M; Romani, L; Ballot, D; Dramowski, A; Wadula, J; Lochindarat, S; Boonkasidecha, S; Namiiro, F; Ngoc, HTB; Tran, MD; Cressey, TR; Preedisripipat, K; Berkley, JA; Musyimi, R; Zarras, C; Nana, T; Whitelaw, A; da Silva, CB; Jaglal, P; Ssengooba, W; Saha, SK; Islam, MS; Mussi-Pinhata, MM; Carvalheiro, CG; Piddock, LJV; Heath, PT; Malhotra-Kumar, S; Sharland, M; Glupczynski, Y; Goossens, H
(2024)
Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries.
Nat Commun, 15 (1).
p. 3947.
ISSN 2041-1723
https://doi.org/10.1038/s41467-024-48296-z
SGUL Authors: Bielicki, Julia Anna
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
|
|
PDF (Supplementary Information)
Supplemental Material
Download (180kB) | Preview |
|
|
PDF (Peer Review File)
Supplemental Material
Available under License Creative Commons Attribution. Download (3MB) | Preview |
|
|
PDF (Description of Additional Supplementary Files)
Supplemental Material
Download (112kB) | Preview |
|
![]() |
Microsoft Excel (Supplementary Data 1)
Supplemental Material
Download (17kB) |
|
![]() |
Microsoft Excel (Supplementary Data 2)
Supplemental Material
Download (25kB) |
|
|
PDF (Reporting Summary)
Supplemental Material
Download (2MB) | Preview |
Abstract
Gram-negative bacteria (GNB) are a major cause of neonatal sepsis in low- and middle-income countries (LMICs). Although the World Health Organization (WHO) reports that over 80% of these sepsis deaths could be prevented through improved treatment, the efficacy of the currently recommended first- and second-line treatment regimens for this condition is increasingly affected by high rates of drug resistance. Here we assess three well known antibiotics, fosfomycin, flomoxef and amikacin, in combination as potential antibiotic treatment regimens by investigating the drug resistance and genetic profiles of commonly isolated GNB causing neonatal sepsis in LMICs. The five most prevalent bacterial isolates in the NeoOBS study (NCT03721302) are Klebsiella pneumoniae, Acinetobacter baumannii, E. coli, Serratia marcescens and Enterobacter cloacae complex. Among these isolates, high levels of ESBL and carbapenemase encoding genes are detected along with resistance to ampicillin, gentamicin and cefotaxime, the current WHO recommended empiric regimens. The three new combinations show excellent in vitro activity against ESBL-producing K. pneumoniae and E. coli isolates. Our data should further inform and support the clinical evaluation of these three antibiotic combinations for the treatment of neonatal sepsis in areas with high rates of multidrug-resistant Gram-negative bacteria.
Item Type: | Article | |||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Additional Information: | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2024 | |||||||||||||||||||||||||||||||||
Keywords: | Humans, Anti-Bacterial Agents, Neonatal Sepsis, Infant, Newborn, Gram-Negative Bacteria, Gram-Negative Bacterial Infections, Acinetobacter baumannii, Microbial Sensitivity Tests, Klebsiella pneumoniae, Amikacin, Fosfomycin, beta-Lactamases, Escherichia coli, Developing Countries, Drug Resistance, Multiple, Bacterial, Drug Therapy, Combination, Serratia marcescens, Enterobacter cloacae, Bacterial Proteins, Humans, Gram-Negative Bacteria, Acinetobacter baumannii, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Gram-Negative Bacterial Infections, Fosfomycin, beta-Lactamases, Amikacin, Bacterial Proteins, Anti-Bacterial Agents, Drug Therapy, Combination, Microbial Sensitivity Tests, Drug Resistance, Multiple, Bacterial, Developing Countries, Infant, Newborn, Neonatal Sepsis | |||||||||||||||||||||||||||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | |||||||||||||||||||||||||||||||||
Journal or Publication Title: | Nat Commun | |||||||||||||||||||||||||||||||||
ISSN: | 2041-1723 | |||||||||||||||||||||||||||||||||
Language: | eng | |||||||||||||||||||||||||||||||||
Dates: |
|
|||||||||||||||||||||||||||||||||
Publisher License: | Creative Commons: Attribution 4.0 | |||||||||||||||||||||||||||||||||
Projects: |
|
|||||||||||||||||||||||||||||||||
PubMed ID: | 38729951 | |||||||||||||||||||||||||||||||||
Go to PubMed abstract | ||||||||||||||||||||||||||||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/116500 | |||||||||||||||||||||||||||||||||
Publisher's version: | https://doi.org/10.1038/s41467-024-48296-z |
Statistics
Actions (login required)
![]() |
Edit Item |